We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




A Better Way to Deliver Dendritic Cell Vaccines

By Biotechdaily staff writers
Posted on 20 May 2002
An animal study has shown that a new method of delivering dendritic cell vaccines is much faster and less expensive than the conventional method. More...
Conducted by scientists at the University of Texas Southwestern Medical Center (UT, Dallas, USA), the study was published in the December 28, 2002, issue of Nature Biotechnology.

Dendritic cells signal T lymphocytes to multiply and initiate an immune response against bacteria, viruses, and cancer cells and are thus good vaccine candidates. However, the conventional method of culturing cells in a petri dish is a time-consuming, expensive process that has deterred broad vaccine application. Now, a new procedure developed and tested in mice enables researchers to manipulate dendritic cells in the skin instead of a petri dish and reduces the time required from 10 days to 24 hours.

Here is how the new delivery method works. Upon exposure to the chemical hapten, immature dendritic cells in the epidermis known as Langerhans cells mature and migrate to draining lymph nodes. A key chemokine (MIP3beta) helps to attract the migrating cells and mediate the migration process. The researchers created an artificial trap for Langerhans cells by implanting a polymer rod under the skin that was synthesized with ethylene-vinyl-acetate to release this chemokine. After the rod was implanted, hapten was applied to trigger the Langerhans cell migration. The cells homed in to the lymph nodes and created an accumulation of Langerhans cells around the rod.

In a second experiment, the researchers utilized a polymer rod releasing a tumor-associated antigen that was implanted under the skin, believing that the Langerhans cells would carry the antigen to the draining lymph nodes and initiate immunity against tumor development. Subsequent experiments with different tumor models have demonstrated that this strategy is efficacious.

"We believe that our in situ Langerhans cell vaccine format represents a breakthrough in the tumor vaccines field, thus moving it toward practical medicine,” said Dr. Akira Takashima, professor of dermatology at UT Southwestern.




Related Links:
University of Texas Southwestern Medical Center

New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Steam Sterilizer
Hi Vac II Line
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.